Specialty Pharma Underperforms S&P 500 For First Time Since 2009 – ValueWalk Premium
Specialty Pharma

Specialty Pharma Underperforms S&P 500 For First Time Since 2009

As the year winds down, good riddance might be a popular sentiment for specialty pharma, which underperformed against the S&P 500 for the first time since 2009 as Martin Shkreli, Epipen "gauging" and Valeant  "scandal" stories took their toll. But the theme for 2017 might not be a whole lot better. Try uncertainty.

Also see
Livermore Partners Huge Gain On Valeant . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

0